Clinical trial
A Multicenter, One-arm Phase II Clinical Study of Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer
NCT05795920 is registered in ClinicalTrials.gov with Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, One-arm Phase II Clinical Study of Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer
- Lead sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- March 8, 2023
- Completion date
- September 8, 2025
- Enrollment
- 92 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.